This is a working overview of copper tripeptide-1, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-22 and is reviewed periodically as new material appears.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
Copper peptide solutions tend to resist degradation better than many free peptides, because the bound metal protects the N-terminus and reduces susceptibility to some peptidases. Backbone hydrolysis, oxidation of the histidine imidazole ring, and photochemical reactions remain the principal degradation routes. Aqueous solutions are generally most stable near neutral to mildly acidic pH, while strongly alkaline conditions accelerate hydrolysis. Light exposure is usually avoided, since both the peptide and the copper center can take part in photochemical processes. Stability data published by suppliers often describe short-term behavior rather than multi-year shelf life.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) tripeptide complex | Contains glycyl-histidyl-lysine ligand |
| Peptide sequence | Gly-His-Lys | N-terminal glycine, C-terminal lysine |
| Molecular formula | C14H22CuN6O4 | Commonly cited for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility | Water-soluble | Also dissolves in some polar solvents |
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
In November 1949, Pauling, Harvey Itano, S. J. Singer and Ibert Wells published "Sickle Cell Anemia, a Molecular Disease" in the journal Science. It was the first proof of a human disease being caused by an abnormal protein, and sickle cell anemia became the first disease understood at the molecular level. (It was not, however, the first demonstration that variant forms of hemoglobin could be distinguished by electrophoresis, which had been shown several years earlier by Maud Menten and collaborators). Using electrophoresis, they demonstrated that individuals with sickle cell disease have a modified form of hemoglobin in their red blood cells, and that individuals with sickle cell trait have both the normal and abnormal forms of hemoglobin. This was the first demonstration causally linking an abnormal protein to a disease, and also the first demonstration that Mendelian inheritance determines the specific physical properties of proteins, not simply their presence or absence – the dawn of molecular genetics. His success with sickle cell anemia led Pauling to speculate that a number of other diseases, including mental illnesses such as schizophrenia, might result from flawed genetics. As chairman of the Division of Chemistry and Chemical Engineering and director of the Gates and Crellin Chemical Laboratories, he encouraged the hiring of researchers with a chemical-biomedical approach to mental illness, a direction not always popular with established Caltech chemists. In 1951, Pauling gave a lecture entitled "Molecular Medicine".
Dunkin' Donuts LLC, doing business as Dunkin', is an American multinational fast food restaurant chain specializing in coffee and doughnuts. It was founded by Bill Rosenberg in Quincy, Massachusetts, in 1950. The chain was acquired by Baskin-Robbins' holding company Allied Lyons in 1990. Its acquisition of the Mister Donut chain and the conversion of that chain to Dunkin' Donuts facilitated the brand's growth in North America the same year. Dunkin' and Baskin-Robbins eventually became subsidiaries of Dunkin' Brands, headquartered in Canton, Massachusetts, in 2004. Dunkin' Brands was purchased by Inspire Brands on December 15, 2020. The chain began rebranding as a "beverage-led company", and was renamed Dunkin' in January 2019. While stores in the U.S. began using the new name, the company intends to roll out the rebranding to all of its international locations. With approximately 14,200 locations in 39 countries and $14.5 billion in system sales, Dunkin' is one of the largest coffee shop and doughnut shop chains in the world. In addition to several varieties of coffee and doughnuts, products sold include bagels, breakfast sandwiches, muffins, and doughnut holes branded as Munchkins.
Elena Molokhovets's classic Russian cookbook A Gift to Young Housewives gives the first known recipe for Govjadina po-strogonovski, s gorchitseju, "Beef à la Stroganov, with mustard", in its 1871 edition. The recipe involves beef cubes (not strips) prepared in a dry marinade of salt and allspice, and then sautéed in butter. The sauce is a simple roux mixed with prepared mustard and broth, and finished with a small amount of sour cream: no onions, no mushrooms and no alcohol. In 1891, the French chef Charles Brière, who was working in Saint Petersburg, submitted a recipe for beef Stroganoff to a competition sponsored by the French magazine L'Art culinaire. This led Larousse Gastronomique to assume that he was the inventor of this dish, but both the recipe and the name existed before then.
In 1977, Lilly acquired IVAC Corporation, which manufactures vital signs and intravenous fluid infusion monitoring systems. The same year, Lilly acquired Cardiac Pacemakers, Inc., a manufacturer of pacemakers for $127 million. In 1980, Lilly acquired Physio-Control, a pioneering company in defibrillation. Advance Cardiovascular Systems was acquired in 1984 for $85 million in stock. Lilly acquired Hybritech in 1986 for $350 million; it was sold to Beckman Coulter in 1995. In 1988, it acquired Devices for Vascular Intervention for $50 million, with the potential for up to another $150 million in contingent payments. Lilly acquired Pacific Biotech in 1990; it was sold to QuidelOrtho in 1995 for $3.95 million. In 1992, Lilly acquired Origin Medsystems, which was developing several devices for use in laparoscopy. Heart Rhythm Technologies was acquired in 1992. Fluoxetine (Prozac), introduced in 1988, quickly became the company's best-selling product for treatment of depression, but Lilly lost its US patent protection for the product in 2001. Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. In 1989, a joint agrochemical venture between Elanco and Dow Chemical created DowElanco. In 1997, Lilly sold its 40% share in the company to Dow Chemical for $1.2 billion and the name was changed to Dow AgroSciences. In 1991, Vaughn Bryson became president and CEO and Wood became board chairman.
=== Phase 3 === AB-103 – topical – alopecia – minoxidil sulfotransferase stimulant (adjunct to minoxidil) Clascoterone (Breezula, Winlevi; CB-03-01) – topical – alopecia – androgen receptor antagonist Diphencyprone (diphenylcyclopropenone, samcyprone) – topical – alopecia areata – immunomodulator Dutasteride (AD-208) – oral – alopecia – 5α-reductase inhibitor Minoxidil oral extended-release (VDPHL01, VDPHL-01, VDPHL) – oral – alopecia, male pattern baldness – potassium channel opener (prodrug of minoxidil sulfate) Minoxidil sublingual (SLM) – sublingual – alopecia – potassium channel opener (prodrug of minoxidil sulfate) Pyrilutamide (EX-A5504, HY-145451, KX 826) – topical – alopecia – androgen receptor antagonist Upadacitinib (Rinvoq; ABT-494) – oral – alopecia areata – Janus kinase 1 inhibitor
Sources: en.wikipedia.org
Regarding allegations about the 1 September double tap strike that killed survivors, Sarah Harrison, a former Pentagon legal adviser, told CNN that "They're killing civilians in the first place, and then if you assume they're combatants, it's also unlawful", stating that in the laws covering armed conflict, hors de combat (out of combat) people "no longer able to fight...have to be treated humanely." Experts questioned whether the survivors of the initial explosion could be lawfully targeted, with some describing the allegations about the follow-up strike as potentially constituting an extrajudicial killing. According to these assessments, the legality of the operation depended on whether US forces reasonably believed those targeted remained combatants or posed a continuing threat at the time of the second strike. According to The Guardian, the Trump administration is following a memo from the Office of Legal Counsel that has been "fiercely criticized by outside legal experts" which "says it is permissible for the US to use lethal force against unflagged vessels carrying cocaine since the cartels use the proceeds to fund violence", and by "framing the strikes as specifically targeting the boat ... put the attack on the firmest legal ground". Time magazine reported that experts said the killing of survivors, if true, could be considered murder and a war crime, and that Hegseth could be subject to criminal charges under the Uniform Code of Military Justice, or charged under the US War Crimes Act of 1996.
== Principle == This technique is applicable to gases or any materials that can be vaporized. It uses a non-fragmenting non-conventional ionisation mode, by attachment of a lithium (or alkaline) ion to the gas to be analysed with a more traditional mass filter. This instrument is more dedicated to analysis of moderately-sized molecules such as organic or aromatic compounds.
However, nutmeg extracts were found to weakly inhibit the endocannabinoid-metabolizing enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) (IC50Tooltip half-maximal inhibitory concentration = 11,370–21,060 nM with different fractions) and to produce antidepressant- and anxiolytic-like effects in rodents. Individual nutmeg constituents such as licarin A, 5′-methoxylicarin A (odoratisol A), and malabaricone C were subsequently found to act as weak FAAH inhibitors (IC50 = 4,570–38,290 nM) and 5′-methoxylicarin A produced anxiolytic-like effects without affecting locomotor activity. Other studies have found nutmeg extracts to produce anxiogenic effects on the other hand. Effects of nutmeg on anxiety may be dose-dependent analogously to cannabis. More research is needed to identify the constituents of nutmeg responsible for its MAGL inhibition. By inhibiting FAAH and/or MAGL, nutmeg may elevate levels of endocannabinoids such as anandamide (AEA) and 2-arachidonylglycerol (2-AG) and thereby indirectly activate cannabinoid receptors such as the CB1 and CB2 receptors. There is evidence that nutmeg, in addition to FAAH and MAGL inhibition, may also non-selectively inhibit other enzymes, which could produce additional effects and side effects. Trimyristin, a triglyceride found in nutmeg, has shown various behavioral effects in rodents such as depressive- and anxiogenic-like effects.
=== Medication shortages === Trends on TikTok have contributed to the shortages of some medications. Danish pharmaceutical company Novo Nordisk produces three medications containing the active ingredient semaglutide. One of the drugs, Wegovy, is certified by the Food and Drug Administration for the treatment of obesity. The other two, Ozempic and Rybelsus, are only certified for the treatment of diabetes. In 2022, the United States suffered shortages of Ozempic after it became a trend on the platform to use the medication off-label for its weight loss effects. Australia's Therapeutic Goods Administration reported that Ozempic's popularity on TikTok had contributed to a global shortage of the medication. It recommended that doctors not prescribe the medication to new patients and prescribe alternative medications to existing patients where possible. By March 2023, TikTok videos posted with the hashtag #Ozempic had amassed 690 million views.
Sources: en.wikipedia.org
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.
Yes, it is found in human plasma, saliva, and urine. Its concentration in plasma tends to decrease with age. This natural presence is one reason researchers have investigated its role in tissue maintenance.
No, GHK-Cu is not an approved drug in major markets. It is widely used as a cosmetic ingredient, where it is listed under names such as copper tripeptide-1. Any therapeutic claims would require separate regulatory review.
The solid is typically held cold and dry, and solutions are kept for shorter periods because hydrolysis proceeds in water. Repeated freeze-thaw cycles are usually avoided, since they can degrade both the peptide and the complex. Container material and headspace also affect how long a sample remains unchanged.